Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-100 (miR-100) is a naturally occurring microRNA that acts as a tumor suppressor in various malignancies, including glioblastoma multiforme (GBM). It functions by post-transcriptionally regulating gene expression, specifically targeting the Silencing Mediator for Retinoid and Thyroid Hormone Receptors (SMRT), also known as Nuclear Receptor Corepressor 2 (NCOR2). In glioblastoma, miR-100 expression is typically downregulated compared to normal brain tissue. Preclinical research has demonstrated that the delivery of miR-100 precursors or mimics can inhibit tumor cell proliferation, induce apoptosis, and significantly extend survival in intracranial xenograft models. These effects are mediated through the downregulation of SMRT, which in turn reduces the Ki-67 proliferation index and triggers programmed cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-100.